IL-33/ST2 Axis as a Well-Known Endogenous Defense Against Tuberculosis

Document Type : Systematic review

Authors

1 Department of Microbiology and Virology, Faculty of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran

2 Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Tuberculosis (TB) infection is caused by an intracellular bacterium, Mycobacterium tuberculosis (Mtb). The disease is among the most important infectious diseases, which has dedicated most cases of morbidity and mortality to itself worldwide. The global report of World Health Organization (WHO) in 2019 shows that from 10.7 million infected people in 2018, 1.6 million died. Although the BCG vaccine has been used for about a hundred years, it is only effective in children, but is not able to produce a protective and reliable immunity against adult pulmonary TB. Hence, using an alternative vaccine with high more efficacy than BCG seems to be urgent. The IL-33/ST2 axis forms of IL-33 and ST2, and both of them are the members of IL-1 family. IL-33 is secreted as an alarm in response to cell damages and cellular stress, and ST2 causes stimulation of MyD88/NF-κB signaling pathway, which is needed for the proper response of infected cells to Mtb and other intracellular pathogens. In Th2 cells, NF-κB enters into the nucleus, and acts as a transcription factor. Finally, cytokines such as IL-4, IL-5, and IL-10 are produced which are effective in the prevention of tissue damage. Based on various information, it is recommended that IL-33 can be as a novel therapeutic candidate in post-exposure cases of TB disease.

Keywords


Nowadays, notable progressions have been done in the diagnosis and treatment of tuberculosis (TB) infection. However, TB remains one of the major causes of morbidity and mortality worldwide. According to WHO report in 2019, from 10.7 million involved people with this microorganism, 1.6 million died in 2018 (1,2).
In addition, it is estimated that one-fourth of people in all of the words affected to latent form of TB that with time, 5-10% of them afflicted to reactivation of TB (3).
As soon as the entrance into the lung, Mycobacterium tuberculosis (Mtb) is surrounded by alveolar macrophages, and phagocytized through in

teraction with specific receptors. Depend on host epigenetic conditions, there are three categories of TB infections containing:1) active TB infection (ATBI) in health and immunocompromised individuals;2) aborted infection in healthy individuals, due to proper activity of classic (M1) macrophages; 3) Latent tuberculosis infection (LTBI), due to remaining in alternative (M2) macrophages (4,5).
Based on current documents, immune system changes play a pivotal role in the determination of Mtb pathogenesis, as well as in the formation of different outcomes in Mtb infection (6,7).
The IL-33/ST2 axis is one of the immune

system components, which its role has been demonstrated in tuberculosis pathogenesis, cancer, hypersensitivity diseases, myocardial infraction, inflammatory bowel disease (IBD), as well viral diseases such as HIV and HBV (8,9).
Interleukin 33 (IL-33) is one of the classic members of the family of IL-1, which is secreted as an alarm in response to cell damages and cellular stress in non-hematopoietic cells such as endothelial, fibroblast, adipocyte cells, as well as, lung and intestinal epithelial cells, and hematopoietic cells such as dendritic cells (DCs) and macrophges (10,11).
This interleukin may have cleaved by chymase, tryptase, elastase, neutrophil serine protease. Evidence suggests that the cleaved form of IL-33 has 10-30 fold more than the complete form (12).
The function and specific receptor of IL-33 were unknown until recent; but recently it has been determined that IL-33 is a pleiotropic cytokine. The immune-modulator function of cytokine is mediated via its specific receptor, Serum stimulation-2 (ST2), which is expressed on the surface of many immune cells including NK cells, CTLs, DCs, basophils, eosinophils, T regulatory (T reg) cells, Th1, Th2, iNKT cells, mast cells, B cells, neutrophils and macrophages (9, 13).
ST2 (or tumorigenicity 2) first was introduced by Tominaga et al. in 1989. ST2 is one of the members of family of IL-1 which is expressed in four forms such as ST2L (a membrane receptor), sST2 (a soluble factor as decoying the ST2L receptor), ST2V (a variant of ST2), and ST2LV (a variant of ST2). Of these, ST2 and sST2 have more studied, so that ST2 causes stimulation of MyD88/NF-κB signaling pathway, but sST2 causes down-regulating of it (9,14, 15).
ST2 is expressed on the surface of many cells, and regulates derivative responses from Th2, T reg cells, and IgE production. (8,9,16).
The sST2 compared to ST2 has a unique region containing 9 amino acids which lead to increase proinflammatory cytokines such as IL-1β, TNF-α in epithelial and monocyte cells (8, 17).
Overall, IL-33/ST2 axis through the affecting on cellular signaling pathways causes to form various massages in immune system cell lines. Among these massages can be mentioned to increase in T reg cells number, stimulate the production of cytokines such as IL-4, IL-5, and IL-10, as well as suppression of IFN-γ and IL-2 in Th2 cells, boost production of TGF-β and IL-4 in Th9 cells, enhance the production of IL-12 in CTLs, production of IL-13, IL-5, and IgM in B1 cells, and also increased production of IL-17 and IFN-γ in NK and iNKT cells (9, 18, 19) (Figure 1).

Based on current information, the footprint of IL-33/ST2 axis has been recognized in many disorders, and also by the effect on a wide spectrum of immune system cells, this axis is able to change the consequence, and is even used as a diagnostic or therapeutic biomarker (8, 9,18-20).
Given that the controversial results, our knowledge about the role of IL-33/ST2 axis in TB pathogenesis is limited. Therefore, the main goal of this study was evaluation of IL-33/ST2 role in the final outcomes of tuberculosis.

Methods
In the present study, we collected all documents about expressive changes of IL-33/ST2 axis, serum IL-33 and ST2 level in different forms of TB disease, and also effects of enhancing or knockout of this axis from Scopus, PubMed, and Web of Science databases.
It is notable that, the search was done by use of keywords such as Interleukin-33 AND Tuberculosis, ST2 AND Tuberculosis, Interleukin-33 AND TB vaccine, Interleukin-33 AND Biomarker, Interleukin-33 AND Diagnosis, Interleukin-33 AND Pleural effusion, ST2 AND Pleural effusion, Interleukin-33 AND Lung infection, and ST2 AND Lung infection; all meta-analysis and review articles were deleted from our study. Following the collection of all information, IL-33/ST2 axis evaluated in terms of different aspects including changes in serum levels during different forms of TB, and its ability as a therapeutic and diagnostic biomarker.

Result
Although IFN-γ and Th1 cell responses are known as the main arm of the immune system, it is notable that the severe and non-controlled responses of Th1 cells and classic macrophages (M1 macrophages) may lead to type IV hypersensitivity. Mostly, severe responses cause tissue damages and caseous necrosis of granuloma, and consequently, Mtb gets out of the TB cavity and causes military TB (21).
Therefore, excessive responses of Th1 should be modulated by TH2 cells, alternative macrophages (M2 macrophages), and T reg cells, and finally, a proper balance created between Th1 and Th2 responses (22, 23). However, many studies have shown that the increased count of T reg and Th2 cells in active and disseminated TB patients (24, 25). Overall, access to a full immunity against Mtb is very complex, and is not dependent on Th1 and IFN-γ responses. In addition, Th2 and T reg cells through the equilibration of Th1 reactions, and also the prevention of hypersensitivity reactions have pivotal role during Mtb infection (26).
According to what was mentioned on the one hand, and available evidence in the other hand, it is demonstrated that ST2 receptor has a great role in protection in support of Th2 cells response, and induction of T reg cells. Hence, as a new approach, this receptor is accounted for prediction and protection of final disorders of TB infection; if this has received less attention (27).

Administration and knockout effects of IL-33/ST2 axis
Wieland et al. designed a project about the effects of IL-33/ST2 axis in infected mouse to Mtb. They contaminated two groups of mice, wild type (WT) and ST2 KO (ST2 knockout) by 150 colony-forming unit (CFU) of Mtb. Assessments showed that clinical manifestations and production of IFN-γ have no significant difference in both groups, and they claimed that ST2 has a very limited role during Mtb infection (28).
Although in previous studies it had been demonstrated that depletion of ST2-secretory cells induce the resistance against Leishmania major, but Wieland’s study disproved this hypothesis in about Mtb infection (29).
Pineros et al. observed that in infected mice to Mtb, following stimulation of Th2 cells with allergens, infection is controlled more appropriately. They infected both BALB/c and ST2 KO groups with Mtb, and then exposed them to ovalbumin (OVA). They showed that allergens caused increase activity in ST2-secretory Th2 cells, as well as significantly less CFU than other groups. In addition, due to higher levels of inflammatory cytokines in this group, they recommended that IL-33 can be as a novel therapeutic candidate in infection with Mtb (30).

Diagnostic biomarker
Toll-like receptor (TLRs) as one of the most important components of the pattern the recognition receptor (PRR) family has a pivotal role against Mtb. Following the recognition of Mtb surface antigens by TLRs in the surface of host cell, an adaptor protein named MyD88, stimulated by TIR (Toll/Interleukin-1 receptor). In the next step, MyD88 in turn activates NF-κB signaling pathway, which leads to induction of the production of IFN-γ and other pro-inflammatory cytokines (31-33). Nevertheless, tuberculous bacilli are a successful pathogen, and through calling and stimulation of negative regulators such as ST2, single immunoglobulin IL-1R related molecule (SIGIRR), Toll-interacting protein (TOLLIP), suppression of cytokine signaling (SOCS), IL-1 receptor associated kinase (IRAK). In addition, this pathogen by containment of NF-κB signaling pathway causes to suppress of immune system response, and consequently freely replication, which leads to military TB (34, 35).
One of the main side effects of pulmonary TB is tuberculous pleural effusion (TPE), which is observed in 30% of extrapulmonary tuberculosis cases (36). In order to proper treatment, TPE should be diagnosed from other pleural effusions. Considering slow growth of Mtb and low sensitivity of the culture on the one hand, and invasive sampling on the other hand, diagnosis of TPE is encountered with many limitations (37).
So scientists are looking for alternative cultivation methods. In this regard, tracking of IL-33 is one the best candidates, which has attracted a lot of attention (38). Based on scientific documentation, during the IFN-γ and TNF-α response, significant amounts of IL-33 secreted in pleural fluid, which in turn improves Th1 cells activity, and also in the presence of ST2L supports production and development of Th2 responses (39, 40).
So far, many studies have been done about the evaluation of interleukin levels in TPE patients, which seems IL-33 is a safe biomarker for differentiation of TPE from other pleural effusions (Table 1).
Table 1. TPE versus other pleural effusions.
Location Cut-off (pg.ml) Significant in TB Test Ref
South Korea 10 Yes ELISA (39)
China 68.3 Yes ELISA (41)
China 19.31 Yes ELISA (42)
South Korea 26 Yes ELISA (38, 39)
Egypt 22.5 Yes ELISA (38)


Unlike IL-33, the relevance of ST2 and severity of TB disease do not have certain evidence and further studies are needed (Table 2). Also, based on our studies, IL-33 serum level in active TB patients significantly is more compared to healthy individuals; although this subject did not true about the sST2.

Table 2. ST2 in TB patients vs healthy group.
Location Cut-off Significant in TB Test Ref
Japan 1.28 ng.ml No RT-PCR (43)
Netherlands 261 pg.ml Yes RT-PCR (44)
South Korea 328 pg.ml No ELISA (39)
Japan 2700 pg.ml Yes ELISA (27)


3.3. Treatment and vaccination
One of the main concerns about the TB is the lack of an effective vaccines for the prevention of pulmonary tuberculosis in adults. In recent, the vaccine is only available vaccine against TB. The vaccine is very effective in the prevention of tuberculous meningitis and also military TB in children, but does not produce a protective and reliable immunity against adult pulmonary TB, reactivation of latent TB, and also in HIV positive patients (5,45).
One of the main limitations of the BCG vaccine is the inability to the induction of T memory cells and thus long-term immunity (5, 45, 46). Vaccine and its adjuvants enhance the activity of B cells and the production of antibodies, while effective immunity against TB infection is related to CMI (47, 48). Appropriate adjuvants via the effect on antigen presenting cells (APCs) stimulate CTLs and Th1 cells, and finally induce a stronger response against TB infection (49, 50). In this regard, IL-33/ST2 axis plays an important role. Nowadays it is known that this axis effect on both Th1 and Th2 cell groups, and therefore new vaccine candidates have produced based on the proposed axis. For example, blocking of ST2 by use of monoclonal antibody IgG-ST2, leads to a decline of created allergic reactions in upper respiratory tracts due to excessive activity of Th2 cells (51, 52). In recent, many of therapeutic agents such as sST2, IL-33 and ST2 inhibitors for the treatment of gastrointestinal inflammation, Graft versus host disease (GVHD), cardiovascular disorders, asthma, and chronic obstructive pulmonary disease (COPD) are in clinical trial I and II phases (9). Currently, anti-tuberculosis vaccine candidates of IL-33/ST2 axis, are more designed based on post-exposure vaccines. The root of utilizing of IL-33/ST2 vaccine is the presence of strong adjuvants such as CAF01, which are able to simulate of IL-33/ST2 signaling pathway (5, 34, 53-55). Available information show that, subsequent IL-33/ST2 signaling pathway, activated MyD88 adaptor can stimulate and enhance Th1/Th2 response. As a result, high level of IFN-γ is produced, which in turn causes activation of M1 macrophages and finally intracellular lysis of Mtb (34, 55). According to review of literatures, so far two types of vaccines have been produced from this generation (53, 56). Desel et al. designed a study based on central role of MyD88 in immunization against TB infection by subunit vaccines. They immunized different groups of MyD88-/- and Mincle-/-C57BL/6 mice against TB, by use of H1 (Ag85B-ESAT6) subunit vaccine, along with trehalose-6,6-dibehenate (TDB). In their research, they demonstrated that following injection of TDB adjuvant, expression level of IL1A and IL1B genes increase in mice. Therefore, stronger immune responses of Th1 and Th17 cells was observed in mice which had higher level of IL-1 family (IL-33 and ST2) genes (53).
According to Villarreal et al. studies, it is found that the mice which were immunized with IL-33 in addition to DNA vaccine encoding Ag85B, had higher levels of IFN-γ and TNF-α than the group vaccinated with Ag85B alone (52).
Based on what was mentioned, it is recommended that immunization with anti-tuberculosis vaccines along with supportive adjuvants of IL-33/ST2 (MyD88-dependent) signaling pathway can be accounted as a novel approach for enhancing of protective effects of post-exposure vaccines.

Discussion
Tuberculosis has one of the great public health concern in recently decades which in turn, it has more challenge such as the emergence of drug-resistant TB strains, coinfection with HIV, as well as the presence of a quarter of the world is contaminated with LTBI which 5-15 present of these were develop to active TB (57).
In relation to reactivation TB it is suggested significant documents about evaluation of T regulatory and Th2 cells count and activities in blood samples during active TB compare than LTBI phase (58). It has been concluded that immune-suppuration was occurred following support of Th2/Treg activities in reactive and primary active TB cases (58-59).
Although Th1 immunity response is crucial for elimination and clearance of Mtb within macrophages; But type 1 immunity can be cause of tissue damage and destructive if not restricted (60).
Usually, immune-system has various strategies to reduce exaggerated type I immunity response such as development and support of Th2/Treg cells (61). There is evidence which destructive epithelial cells in granuloma can produce IL-33 which could be impressed the Treg/Th2 cell activities using ST2L receptor (41,56).
The IL-33/ST2L signaling has various immune-modulatory effects that depend on immune cell lines, microenvironment stimulation signals, and epigenetic events which may result of NF_kB activation (inflammatory response) to MAPKs signaling pathway (P38 stimulation and Th2/Treg activation) (Figure 2) (13,18).
Beside of negative opinion in association with activity of Treg/Th2 cells in TB for it immune-suppuration function (58); there is numerous evidence which supported from efficient roles of Th2 cells during TB infections (62,63).
Treg/Th2 activities can be useful for TB using various function such as 1) reduction of tissue damage,2) reduction of exaggerative Th1 response,3) enhance and support of antioxidant capacity,4) development of humoral immunity for example production of antibody and making efficient antigen presenting cells (APCs), and 5) support of innate immunity response (61-65).
The IL-33 is one of the important immune-modulatory cytokines which can produce in numerous cell lines of hematopoietic and non-hematopoietic in results of infection and cell damage (9).
There are numerous studies which are relied on efficacy of IL-33 level for diagnosis and monitoring of pulmonary complication particularly tuberculosis (39-42).

It seems that IL-33 is appropriate potential biomarker for monitoring of tuberculosis during LTBI phase and treatment cases (40,42).
In the other hand, IL33/ST2L has immune-modulatory effects which is support Th2 response as well as induction of inflammatory process by triggering NF_κB signaling pathway (8-9).
In healthy condition, the type I immunity response ownregulated by Th2 activities after clearance of infectious agents and the balance between Th1 and Th2 was essential for appropriate function and hemostasis (66).
According to review of the literatures, IL-33/ST2L axis has important role in TB infection with switching between Th1 and Th2 response (57).
Moreover, due to immune-modulatory effects of this axis, the molecular targeting of the IL-33/ST2L axis can novel approach in development of immune-therapy of tuberculosis (13).

Conclusion
According to review of the literatures, IL-33 as one of the important cell-damage response can be produced by epithelial cells in results of tissue destruction which caused by Th1 response in active-TB; the ST2L is specific receptor of IL-33 which produce by immune-cells particularly Th2 cells. The IL-33/ST2L axis has immune-modulatory effects by impressed various signaling network which used to making balance between Th1 and Th2 responses and can be useful in development of novel approach in diagnosis and treatment of TB.

Conflicts of interest
The authors declare no conflicts of interest.

  1. Keikha M, Esfahani BN. The relationship between tuberculosis and lung cancer. Adv Biomed Res. 2018;7:58.
  2. Knight GM, McQuaid CF, Dodd PJ, et al. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;19:903-912.
  3. Snow KJ, Sismanidis C, Denholm J, et al. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J. 2018;51:1702352.
  4. Babaki MKZ, Taghiabadi M, Soleimanpour S, et al. Mycobacterium tuberculosis Ag85b: hfcγ1 recombinant fusion protein as a selective receptor-dependent delivery system for antigen presentation. Microb Pathog. 2019;129:68-73.
  5. Khademi F, Derakhshan M, Yousefi-Avarvand A, et al. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost? Expert review of vaccines. 2018;17:31-44.
  6. Cooper AM, Flynn JL. The protective immune response to Mycobacterium tuberculosis. Curr Opin Immunol. 1995;7:512-516.
  7. O’Garra A, Redford PS, McNab FW, et al. The immune response in tuberculosis. Annu Rev Immunol.2013;31:475-527.
  8. De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev. 2015;26:615-623.
  9. Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol.2017;8:475.
  10. Cayrol C, Girard J-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31-37.
  11. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8:22.
  12. Dinarello CA. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor.Immunity. 2005;23:461-462.
  13. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827-840.
  14. Tago K, Noda T, Hayakawa M, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285:1377-1383.
  15. Tominaga S-i, Ohta S, Tago K. Soluble form of the ST2 gene product exhibits growth promoting activity in NIH-3T3 cells. Biochem Biophys Rep. 2015;5:8-15.
  16. Wasserman A, Ben-Shoshan J, Entin-Meer M, et al. Interleukin-33 augments Treg cell levels: a flaw mechanism in atherosclerosis. Isr Med Assoc J. 2012;14:620-623.
  17. Kumar S, Tzimas MN, Griswold DE, et al. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun. 1997;235:474-478.
  18. Milovanovic M, Volarevic V, Radosavljevic G, Jet al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012;52:89-99.
  19. Vocca L, Di Sano C, Uasuf CG, et al. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology. 2015;220:954-963.
  20. Rostan O, Arshad MI, Piquet-Pellorce C, et al. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases. Infect Immun. 2015;83:1738-1748.
  21. Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 2002;295:336-338.
  22. Brighenti S, Joosten S. Friends and foes of tuberculosis: modulation of protective immunity. J Intern Med. 2018;10.1111/joim.12778.
  23. Hernandez-Pando R, Rook G. The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology. 1994;82:591-595.
  24. Keikha M, Shabani M, Navid S, et al. What is the role of” T reg Cells” in tuberculosis pathogenesis? Indian J Tuberc. 2018;65:360-362.
  25. Sharma SK, Mohan A, Sharma A. Challenges in the diagnosis & treatment of miliary tuberculosis. Indian J Med Res. 2012;135:703-730.
  26. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med. 1998;157:679-691.
  27. Watanabe M, Takizawa H, Tamura M, et al. Soluble ST2 as a prognostic marker in community-acquired pneumonia. J Infect. 2015;70:474-482.
  28. Wieland CW, van der Windt GJ, Florquin S, et al ST2 deficient mice display a normal host defense against pulmonary infection with Mycobacterium tuberculosis. Microbes Infect. 2009;11:524-530.
  29. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787-794.
  30. Piñeros A, Campos L, Fonseca D, et al. M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection. Sci Rep. 2017;7:41240.
  31. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637-650.
  32. Kornfeld H, Mancino G, Colizzi V. The role of macrophage cell death in tuberculosis. Cell Death Differ. 1999;6:71-78.
  33. Thada S, Valluri V, Gaddam S. Influence of Toll‐Like Receptor Gene Polymorphisms to Tuberculosis Susceptibility in Humans. Scand J Immunol. 2013;78:221-229.
  34. Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5:446-458.
  35. Yoshida A, Inagawa H, Kohchi C, et al. The role of toll-like receptor 2 in survival strategies of Mycobacterium tuberculosis in macrophage phagosomes. Anticancer Res. 2009;29:907-910.
  36. Qiu L, Teeter LD, Liu Z, et al. Diagnostic associations between pleural and pulmonary tuberculosis. J Infect. 2006;53:377-386.
  37. Zeng N, Wan C, Qin J, et al. Diagnostic value of interleukins for tuberculous pleural effusion: a systematic review and meta-analysis. BMC Pulm Med. 2017 Dec 8;17:180.
  38. Al-aarag A-sH, Kamel MH, Abdelgawad ER, et al. Diagnostic role of interleukin-33 in the differentiation of pleural effusions especially tuberculous and malignant effusions. BMC Pulm Med. 2019;19:114.
  39. Lee K-S, Kim H-R, Kwak S, et al. Association between elevated pleural interleukin-33 levels and tuberculous pleurisy. Ann Lab Med. 2013;33:45-51.
  40. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384:105-109.
  41. Li D, Shen Y, Fu X, et al. Combined detections of interleukin-33 and adenosine deaminase for diagnosis of tuberculous pleural effusion. Int J Clin Exp Pathol 2015;8:888-893.
  42. Liu J, Zhang L, Feng S, et al. Evaluating the value of detecting cytokines for diagnosis of tuberculous pleural effusion by liquid array technology. Chinese Journal of Laboratory Medicine. 2015:562-566.
  43. Oshikawa K, Yanagisawa K, Ohno S, Tet alY. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med. 2002;165:1005-1009.
  44. Blok DC, Kager LM, Hoogendijk AJ, et al. Expression of inhibitory regulators of innate immunity in patients with active tuberculosis. BMC Infect Dis. 2015;15:98.
  45. Keikha M, Moghim S, Fazeli H, et al. The fusion multistage synthetic peptides as the best candidates for new tuberculosis vaccine. Adv Biomed Res. 2018;7:122.
  46. Babaki MKZ, Soleimanpour S, Rezaee SA. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microb Pathog. 2017;112:20-29.
  47. Davidsen J, Rosenkrands I, Christensen D, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 2005;1718:22-31.
  48. Werninghaus K, Babiak A, Groß O, et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ–Syk–Card9–dependent innate immune activation. J Exp Med. 2009;206:89-97.
  49. Singh M, O’Hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 1999;17:1075-1081.
  50. Wack A, Baudner BC, Hilbert AK, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2008;26:552-561.
  51. Löhning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A. 1998 9;95:6930-6935.
  52. Villarreal DO, Wise MC, Walters JN, et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 2014;74:1789-1800.
  53. Desel C, Werninghaus K, Ritter M, Jet al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One. 2013;8:e53531.
  54. Khoshnood S, Heidary M, Haeili M, et al. Novel vaccine candidates against Mycobacterium tuberculosis. Int J Biol Macromol. 2018 Dec;120:180-188.
  55. Haraldsen G, Balogh J, Pollheimer J, et al. Interleukin-33–cytokine of dual function or novel alarmin? Trends Immunol. 2009;30(5):227-233.
  56. Villarreal DO, Siefert RJ, Weiner DB. Alarmin IL-33 elicits potent TB-specific cell-mediated responses. Hum Vaccin Immunother. 2015;11:1954-1960.
  57. Keikha M. Williamsia spp. are emerging opportunistic bacteria. New Microbes New Infect. 2017;21:88-89.
  58. Keikha M, Soleimanpour S, Eslami M, et al. The mystery of tuberculosis pathogenesis from the perspective of T regulatory cells. Meta Gene. 2020;23:100632.
  59. Luo J, Zhang M, Yan B, et al. Imbalance of Th17 and Treg in peripheral blood mononuclear cells of active tuberculosis patients. Brazilian Journal of Infectious Diseases. 2017;21:155-161.
  60. Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflamm. 2015;2015:854507.
  61. Soto GF, Cedeño NV, de Fernández CA, et al. Mycobacterium tuberculosis infection: Participation of TH1, TH2, TH17 and regulatory T cells in the immune response. Acta Medica Iranica. 2018:484-493.
  62. Seddon JA, Chiang SS, Esmail H, et al. The wonder years: what can primary school children teach us about immunity to Mycobacterium tuberculosis?Front Immunol. 2018;9:2946.
  63. Chen T, Li Z, Yu L, et al. Profiling the human immune response to Mycobacterium tuberculosis by human cytokine array. Tuberculosis (Edinb). 2016;97:108-117.
  64. Alvarez N, Serpa D, Kadir R, et al. Specific and cross-reactive immune response against Mycobacterium tuberculosis antigens in mice immunized with proteoliposomes from Mycobacterium bovis BCG. Asian Pacific Journal of Tropical Biomedicine. 2017;7:188-192.
  65. Mosavat A, Soleimanpour S, Farsiani H, et al. Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine. Infection, Genetics and Evolution. 2016;39:163-172.
  66. Wu QI, Wang Q, Mao G, et al. Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients. J Immunol. 2017;198:3069-3080.